AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01496131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
Study NCT01496131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
Study NCT01496131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m\^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
Study NCT01496131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecemotide (L-BLP25)
Description: Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
Study NCT02614859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Observation and Bicalutamide
Description: Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg daily, orally, continuously to the end of study (week 32).
Study NCT02614859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Bicalutamide
Description: Cycles 1-2: Metformin 1000mg BID Cycles 3-8: Bicalutamide 50 mg daily and Metformin 1000 mg BID
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (0.17% saline)
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.17% saline)
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-371 + HS
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT02871778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor
Study NCT04568278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO-CTCAE application
Description: The intervention will be the use of a mobile application for recording symptoms during cancer treatments. Patients in the intervention group will have the mobile application (e-PRO) installed on their smart phones on the first day of cancer treatment (chemotherapy or radiation therapy) and patients will be asked to use the application for 8 weeks. Every week, the application will ask patients to report symptoms they experienced during past 7 days using the pre-specified PRO-CTCAE questions for different types of cancer. Patients also can memo and save photos related symptoms using the application and patients can monitor the progression of the symptoms over time.
Study NCT01329679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Energy drink, 2oz twice daily for 7 days
Study NCT01329679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water, lime juice and cherry flavoring
Study NCT01375257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral treatment with antibiotics for endocarditis
Study NCT01375257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline treatment with parenteral antibiotics
Study NCT02512809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Study NCT02512809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT01396226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2927
Description: A single dose of AZD2927 administered as an iv infusion
Study NCT01396226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo administered as an iv infusion
Study NCT05784493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study group
Description: Washing by heated saline group
Study NCT00912197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligofructose
Description: Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
Study NCT00912197 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
Study NCT03965936 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lipofilling
Description: Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
Study NCT03965936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lipofilling enriched with adipose tissue derived stem cells
Description: Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region.
Study NCT03440099 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercise training
Description: 16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
Study NCT03979690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NISInspire-C System
Description: The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
Study NCT01944683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01944683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GGF2
Study NCT01944683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Study NCT01944683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Study NCT00403676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up bu a nurse
Description: Follow up bu a nurse
Study NCT00403676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up by a medical doctor
Description: Follow up by a medical doctor
Study NCT01218464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus MSC treatment
Description: Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5\*10E6 MSC/kg body for 12 weeks.
Study NCT01218464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional plus pacebo treatment
Description: Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study NCT03975920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Restful Jaw Device
Description: The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
Study NCT01713621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439
Description: OZ439 is a novel synthetic trioxolane antimalarial agent
Study NCT05786079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Footstrike modification
Study NCT05786079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT04300699 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional Geriatric Assessment
Description: A series of 8 self-completed questionnaires for the identification of functional deficits which will be addressed via algorithm-guided interventions and assessments.
Study NCT01371136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: curricular training
Description: Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver.
Study NCT00474708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effexor
Study NCT00474708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Study NCT04035018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacopuncture therapy
Description: The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
Study NCT04035018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The participants in the control group will be receive one or more physical therapy according to the physician's decision.
Study NCT01030159 — intervention group
Intervention type: OTHER
Intervention: Adult Cancer Patients
Description: Tracking anemia management in Adult Cancer Patients
Study NCT00480181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nabilone
Description: Cesamet (nabilone) capsules given at titrating dosages as per protocol.
Study NCT00480181 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
Study NCT00738153 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT03039231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freespira Breathing System
Description: Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
Study NCT01444248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/ Metformin
Description: 4/1000mg once daily
Study NCT01444248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride/ Metformin
Description: 4/1000mg bid
Study NCT01018628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRT2379
Description: SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
Study NCT01018628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
Study NCT04519359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stop NAs therapy
Description: Stop NAs therapy
Study NCT03837782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive surgery
Description: Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
Study NCT04312685 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra II Programmable Pump system - Flowonix Medical
Description: This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
Study NCT00290342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa-IPV
Description: 3 intramuscular injections
Study NCT00290342 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa
Description: 3 intramuscular injections
Study NCT00290342 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IMOVAX Polio®
Description: 3 intramuscular injections
Study NCT03221491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia(PCA)
Description: Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
Study NCT02535884 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ACTIVA® PC neurostimulator (Model 37601)
Description: the stimulator in the stimulation group will be turned on after implantation of the device
Study NCT02535884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVA® PC neurostimulator (Model 37601)
Description: the stimulator in the stimulation group will be turned on after implantation of the device
Study NCT01056510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
Study NCT01056510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil
Description: 10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
Study NCT01056510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
Study NCT01824992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yallaferon®
Study NCT04475575 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Aeonose
Description: All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
Study NCT03013673 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04810182 — intervention group
Intervention type: DRUG
Intervention: Regorafenib 40 MG Oral Tablet [STIVARGA]
Description: As per the treating physicians discretion
Study NCT03854929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor
Study NCT03854929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis.
Study NCT02023242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
Study NCT02023242 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Trabecular Micro Bypass
Description: Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
Study NCT01793142 — intervention group
Intervention type: DRUG
Intervention: Viviant
Description: Viviant (Bazedoxifene) 20mg once daily
Study NCT02782520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate (10ml/kg) fluid expansion
Study NCT02782520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3ml/kg) fluid expansion
Study NCT00279019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705
Description: GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
Study NCT00279019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
Study NCT00279019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
Study NCT02695992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Dosage 100 mg o.d.
Study NCT02695992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: Dosage 360 mg o.d.
Study NCT00771134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AA39959
Description: 30mg/day; 15mg B.I.D. for 8 weeks
Study NCT00771134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: B.I.D. for 8 weeks
Study NCT00771134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 300mg/day for 8 weeks
Study NCT01898572 — intervention group
Intervention type: OTHER
Intervention: Standard care
Description: Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
Study NCT02601677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
Study NCT02601677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
Study NCT03622463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antroquinonol
Description: Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
Study NCT03622463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Study NCT03622463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Study NCT02694770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neihulizumab Treatment
Description: Monoclonal antibody
Study NCT02694770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: 2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
Study NCT01640652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenPF-1.
Description: A new vaccine against meningococcal disease.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Twelve subjects (male: 4 female: 8) consumed 25g glucose diluted in 150ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.